CO5570659A2 - Composiciones de valdecoxib de disgregacion intraoral - Google Patents
Composiciones de valdecoxib de disgregacion intraoralInfo
- Publication number
- CO5570659A2 CO5570659A2 CO04028410A CO04028410A CO5570659A2 CO 5570659 A2 CO5570659 A2 CO 5570659A2 CO 04028410 A CO04028410 A CO 04028410A CO 04028410 A CO04028410 A CO 04028410A CO 5570659 A2 CO5570659 A2 CO 5570659A2
- Authority
- CO
- Colombia
- Prior art keywords
- composition
- pharmaceutically acceptable
- approximately
- oral
- valdecoxib
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1.- Una composición oral fast-melt que comprende:(a) valdecoxib en forma de partículas en una cantidad terapéuticamente eficaz, (b) al menos un retardador de la disolución farmacéuticamente aceptable, y (c) al menos un excipiente farmacéuticamente aceptable que presenta una disolución oral rápida;siendo la composición organolépticamente aceptable.2.- La composición de la reivindicación 1 que, cuando se somete al ensayo número 701 de disgregación in vitro de la Farmacopea de los Estados Unidos 24, presenta un tiempo de disgregación menor de aproximadamente 300 segundos.3.- La composición de la reivindicación 1 que se disgrega en aproximadamente 60 segundos después de ponerse en la cavidad oral de un sujeto humano.4.- La composición de la reivindicación 1, en la que el "al menos un retardador de la disolución farmacéuticamente aceptable" es un polímero.5.- La composición de la reivindicación 4, en la que el polímero está presente en una cantidad total de aproximadamente 0,5% a aproximadamente 15% en peso.6.- La composición de la reivindicación 1, en la que el "al menos un retardador de la disolución farmacéuticamente aceptable" se selecciona entre el grupo compuesto por etilcelulosa, hidroxipropilmetilcelulosa, polivinilpirrolidona, Eudragit® EP O y productos equivalentes de polimetacrilato, hidroxipropiletilcelulosa e hidroxipropilcelulosa.7.- La composición de la reivindicación 1, en la que el "al menos un retardador de la disolución farmacéuticamente aceptable" es Eudragit® EP O o un producto de polimetacrilato equivalente.8.- La composición de la reivindicación 1, en la que el "al menos un excipiente farmacéuticamente aceptable que presenta una disolución oral rápida" es un carbohidrato.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32535601P | 2001-09-26 | 2001-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5570659A2 true CO5570659A2 (es) | 2005-10-31 |
Family
ID=23267542
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO04028409A CO5570684A2 (es) | 2001-09-26 | 2004-03-26 | Composiciones de disgregacion intraoral organolepticamente aceptables |
| CO04028410A CO5570659A2 (es) | 2001-09-26 | 2004-03-26 | Composiciones de valdecoxib de disgregacion intraoral |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO04028409A CO5570684A2 (es) | 2001-09-26 | 2004-03-26 | Composiciones de disgregacion intraoral organolepticamente aceptables |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20030181501A1 (es) |
| EP (2) | EP1429736A2 (es) |
| JP (2) | JP2005512964A (es) |
| KR (2) | KR20040058189A (es) |
| CN (2) | CN1633281A (es) |
| AP (2) | AP2004002999A0 (es) |
| AR (1) | AR037239A1 (es) |
| BR (2) | BR0212778A (es) |
| CA (2) | CA2461630A1 (es) |
| CO (2) | CO5570684A2 (es) |
| EA (2) | EA200400357A1 (es) |
| EC (1) | ECSP045029A (es) |
| GE (1) | GEP20063856B (es) |
| HK (1) | HK1079988A1 (es) |
| IL (2) | IL160848A0 (es) |
| IS (2) | IS7177A (es) |
| MA (2) | MA27542A1 (es) |
| MX (2) | MXPA04002652A (es) |
| NO (2) | NO20041258L (es) |
| OA (2) | OA12707A (es) |
| PL (2) | PL369297A1 (es) |
| TN (2) | TNSN04045A1 (es) |
| WO (2) | WO2003026697A2 (es) |
| YU (1) | YU34804A (es) |
| ZA (2) | ZA200401953B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005002557A1 (en) * | 2003-07-03 | 2005-01-13 | Warner-Lambert Company Llc | Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof |
| US20050186271A1 (en) * | 2004-02-24 | 2005-08-25 | Sheskey Paul J. | Process for dispersing a fluid in a mass of solid particles |
| JP5551852B2 (ja) * | 2004-08-10 | 2014-07-16 | 味の素株式会社 | 苦味の低減したナテグリニド含有製剤 |
| JP5209876B2 (ja) * | 2004-12-28 | 2013-06-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 速崩壊性錠剤及びその製造方法 |
| US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| KR20080080318A (ko) * | 2005-12-20 | 2008-09-03 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 지용성 약물을 함유하는 구강내 속붕정 |
| US8865743B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| US8535714B2 (en) | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| US8202535B2 (en) | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
| US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
| WO2007087188A2 (en) * | 2006-01-20 | 2007-08-02 | Merck & Co., Inc. | Taste-masked tablets and granules |
| US20070196494A1 (en) * | 2006-02-17 | 2007-08-23 | Arnaud Grenier | Low-friability, patient-friendly orally disintegrating formulations |
| CA2687124A1 (en) * | 2006-05-19 | 2007-12-13 | Somaxon Pharmaceuticals, Inc. | Low dose doxepin formulations, including buccal, sublingual and fastmelt formulations, and uses of the same to treat insomnia |
| WO2008148731A1 (de) * | 2007-06-06 | 2008-12-11 | Basf Se | Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten |
| US20100184785A1 (en) * | 2007-06-06 | 2010-07-22 | Basf Se | Pharmaceutical formulation for the production of chewable tablets and lozenges |
| KR20100033400A (ko) * | 2007-06-06 | 2010-03-29 | 바스프 에스이 | 급속 붕해 정제의 제조를 위한 제약 제제 |
| KR20160083132A (ko) * | 2007-06-06 | 2016-07-11 | 바스프 에스이 | 급속 붕해 정제의 제조를 위한 제약 제제 |
| KR101606944B1 (ko) * | 2007-08-07 | 2016-03-28 | 아셀알엑스 파마슈티컬스 인코퍼레이티드 | 경구 경점막 투여형을 사용한 시술시 진정과 무통을 위한 조성물 및 방법 |
| EP2268268A2 (en) * | 2008-03-24 | 2011-01-05 | Wockhardt Research Centre | Orally disintegrating compositions of rhein or diacerein |
| US8945592B2 (en) * | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
| KR101753411B1 (ko) * | 2008-11-25 | 2017-07-03 | 미쓰비시 타나베 파마 코퍼레이션 | 구강 내 속붕괴성정 및 그의 제조 방법 |
| CA2765033C (en) | 2009-06-12 | 2020-07-14 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
| US20110091544A1 (en) * | 2009-10-16 | 2011-04-21 | Acelrx Pharmaceuticals, Inc. | Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting |
| FR2968995B1 (fr) * | 2010-12-16 | 2013-03-22 | Sanofi Aventis | Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage |
| CN106822007B (zh) | 2015-09-11 | 2021-12-31 | 西姆莱斯股份公司 | 口服制剂 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| US5576014A (en) * | 1994-01-31 | 1996-11-19 | Yamanouchi Pharmaceutical Co., Ltd | Intrabuccally dissolving compressed moldings and production process thereof |
| US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| PE10898A1 (es) * | 1995-06-13 | 1998-03-20 | American Home Prod | Formulaciones orales de etodolac s (+)- |
| US5954204A (en) * | 1995-10-20 | 1999-09-21 | Phatmacia & Upjohn Company | Blister package |
| HUP9902889A3 (en) * | 1996-05-17 | 2002-04-29 | Merck Frosst Canada & Co Kirkl | The use of 3-phenyl-4-(4-methylsulphonyl)-phenyl-2-(5h)-furanone for producing anti inflammatory medicaments and such medicaments |
| EP0863134A1 (en) * | 1997-03-07 | 1998-09-09 | Merck Frosst Canada Inc. | 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2 |
| US6465009B1 (en) * | 1998-03-18 | 2002-10-15 | Yamanouchi Pharmaceutical Co., Ltd. | Water soluble polymer-based rapidly dissolving tablets and production processes thereof |
| CA2362816C (en) * | 1999-12-08 | 2007-02-06 | Pharmacia Corporation | Valdecoxib compositions |
| US6316029B1 (en) * | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| US6800297B2 (en) * | 2000-06-15 | 2004-10-05 | Acusphere, Inc. | Porous COX-2 inhibitor matrices and methods of manufacture thereof |
| ATE329583T1 (de) * | 2000-08-18 | 2006-07-15 | Pharmacia Corp | Schnell zerfallende orale arzneizubereitung enthaltend valdecoxib |
| CN1638739A (zh) * | 2000-08-18 | 2005-07-13 | 法玛西雅厄普约翰美国公司 | 治疗成瘾性障碍的化合物 |
-
2002
- 2002-09-23 AP APAP/P/2004/002999A patent/AP2004002999A0/en unknown
- 2002-09-23 OA OA1200400083A patent/OA12707A/en unknown
- 2002-09-23 IL IL16084802A patent/IL160848A0/xx unknown
- 2002-09-23 GE GE5525A patent/GEP20063856B/en unknown
- 2002-09-23 KR KR10-2004-7004334A patent/KR20040058189A/ko not_active Application Discontinuation
- 2002-09-23 BR BR0212778-4A patent/BR0212778A/pt not_active IP Right Cessation
- 2002-09-23 WO PCT/US2002/030048 patent/WO2003026697A2/en active Application Filing
- 2002-09-23 EA EA200400357A patent/EA200400357A1/ru unknown
- 2002-09-23 AP APAP/P/2004/002998A patent/AP2004002998A0/en unknown
- 2002-09-23 PL PL02369297A patent/PL369297A1/xx not_active Application Discontinuation
- 2002-09-23 CN CNA028211413A patent/CN1633281A/zh active Pending
- 2002-09-23 JP JP2003530260A patent/JP2005512964A/ja not_active Withdrawn
- 2002-09-23 BR BR0212861-6A patent/BR0212861A/pt not_active IP Right Cessation
- 2002-09-23 PL PL02369298A patent/PL369298A1/xx not_active Application Discontinuation
- 2002-09-23 CA CA002461630A patent/CA2461630A1/en not_active Abandoned
- 2002-09-23 YU YU34804A patent/YU34804A/sh unknown
- 2002-09-23 EP EP02773522A patent/EP1429736A2/en not_active Withdrawn
- 2002-09-23 OA OA1200400082A patent/OA13060A/en unknown
- 2002-09-23 CA CA002461044A patent/CA2461044A1/en not_active Abandoned
- 2002-09-23 MX MXPA04002652A patent/MXPA04002652A/es unknown
- 2002-09-23 EP EP02775948A patent/EP1490035A1/en not_active Withdrawn
- 2002-09-23 EA EA200400352A patent/EA200400352A1/ru unknown
- 2002-09-23 WO PCT/US2002/030161 patent/WO2003026623A1/en active Application Filing
- 2002-09-23 JP JP2003530331A patent/JP2005506987A/ja not_active Withdrawn
- 2002-09-23 IL IL16085502A patent/IL160855A0/xx unknown
- 2002-09-23 US US10/252,222 patent/US20030181501A1/en not_active Abandoned
- 2002-09-23 KR KR10-2004-7004373A patent/KR20040044990A/ko not_active Application Discontinuation
- 2002-09-23 CN CNA028189078A patent/CN1703203A/zh active Pending
- 2002-09-23 MX MXPA04002798A patent/MXPA04002798A/es unknown
- 2002-09-26 AR ARP020103627A patent/AR037239A1/es unknown
-
2004
- 2004-03-10 ZA ZA200401953A patent/ZA200401953B/en unknown
- 2004-03-11 IS IS7177A patent/IS7177A/is unknown
- 2004-03-11 IS IS7178A patent/IS7178A/is unknown
- 2004-03-23 EC EC2004005029A patent/ECSP045029A/es unknown
- 2004-03-23 TN TNP2004000045A patent/TNSN04045A1/fr unknown
- 2004-03-24 MA MA27587A patent/MA27542A1/fr unknown
- 2004-03-24 TN TNP2004000047A patent/TNSN04047A1/fr unknown
- 2004-03-24 MA MA27586A patent/MA27682A1/fr unknown
- 2004-03-25 NO NO20041258A patent/NO20041258L/no not_active Application Discontinuation
- 2004-03-25 ZA ZA200402364A patent/ZA200402364B/xx unknown
- 2004-03-26 CO CO04028409A patent/CO5570684A2/es not_active Application Discontinuation
- 2004-03-26 CO CO04028410A patent/CO5570659A2/es not_active Application Discontinuation
- 2004-04-15 NO NO20041532A patent/NO20041532L/no not_active Application Discontinuation
-
2006
- 2006-01-04 HK HK06100055.6A patent/HK1079988A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5570659A2 (es) | Composiciones de valdecoxib de disgregacion intraoral | |
| RS115104A (en) | Pramipexole once-daily dosage form | |
| Singh et al. | Review on mucoadhesive drug delivery system with special emphasis on buccal route: an important tool in designing of novel controlled drug delivery system for the effective delivery of pharmaceuticals | |
| DE60121570D1 (de) | Oral anzuwendende schnell zerfallende feste darreichungsformen | |
| Sfondrini et al. | Effects of conventional and high-intensity light-curing on enamel shear bond strength of composite resin and resin-modified glass-ionomer | |
| US6696085B2 (en) | Use of an acrylic type polymer as disintegrating agent | |
| HRP20030951B1 (hr) | Formulacije jednodnevnih doza oksikodona | |
| SE8304393D0 (sv) | Controlled release naproxen and naproxen sodium tablets | |
| MX2009001711A (es) | Formulaciones de liberacion sostenida de topiramato. | |
| JP2005506987A5 (es) | ||
| CY1109636T1 (el) | Συνθεση στοματικης δοσης παρατεταμενης απελευθερωσης | |
| FR2727016B1 (fr) | Compositions pharmaceutiques a base d'ondansetron | |
| EA200000246A1 (ru) | Быстро дезинтегрирующие таблетки метилцеллюлозы | |
| CO5280073A1 (es) | Composiciones | |
| WO2006072940A3 (en) | Controlled long acting release pharmaceutical preparation for use in the oral cavity | |
| JP2005528430A5 (es) | ||
| AP2003002763A0 (en) | Controlled release formulations for oral administration | |
| Fei et al. | Fracture resistance and stress distribution of repairing endodontically treated maxillary first premolars with severe non-carious cervical lesions | |
| PT1425005E (pt) | Composicao farmaceutica que compreende lumiracoxib | |
| HUP0402178A2 (hu) | 5 HT1 antagonista hatóanyagot tartalmazó gyógyszerkészítmény | |
| ES2148766T3 (es) | Derivados de 10-desacetil-14beta-hidroxibaccatina iii, procedimiento para su preparacion y formulaciones que los contienen. | |
| Messerli | Evolution of calcium antagonists: past, present, and future | |
| AR039162A1 (es) | Formulaciones de venlafaxina de liberacion extendida | |
| JP2019515045A (ja) | 甲状腺ホルモン又はそのアナログを提供する組成物及び方法 | |
| JP2009507850A5 (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |